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Thrombocytopenia with
quetiapine: two case
reports, one with positive
rechallenge
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Antipsychotic-induced thrombocytopenia is generally rare,
but seems to occur more frequently with quetiapine.
Accordingly, the relative risk of thrombocytopenia can
be described as very rare with loxapine and clozapine
(o 0.01%), uncommon with risperidone (X 0.1%, o 1%),
but very common with quetiapine (X 10%). However, very
few cases are reported in the literature,1-4 with one published
case of idiopathic thrombocytopenic purpura,1 and it remains
unclear whether rechallenge may be considered.
Patient no. 1 was a 78-year-old male hospitalized for de-
pressive syndrome and treated with mirtazapine 45 mg/day,
valpromide 1,000 mg/day, and oxazepam 30 mg/day.
Quetiapine was added at 50 mg/day, while mirtazapine
was reduced to 30 mg/day. Laboratory tests carried out
the following day and 5 days after the start of treatment
with quetiapine revealed platelet counts of 100,000/mm3
and 56,000/mm3 respectively. Two further measurements
were obtained, 8 days and 28 days after discontinuing
treatment with quetiapine, showing higher platelet levels of
85,000/mm3 and 120,000/mm3 respectively.
Patient no. 2 was a 72-year-old female hospitalized for
personality disorders with hallucinations and treated with
aripiprazole 15 mg/day, clonazepam 0.6 mg/day, valproic
acid 1,500 mg/day, furosemide 40 mg/day, lisinopril
20 mg/day, nebivolol 5 mg/day, and amlodipine 10 mg/day.
During her hospitalization, aripiprazole was stopped and
quetiapine 50 mg/day was introduced. Tests performed
3 months after initiating treatment with quetiapine were
notable for a platelet count of 107,000/mm3. Six days later, a
second test was carried out, and the platelet count was down
to 95,000/mm3. Treatment with quetiapine was suspended
for 3 days, following which the platelet count went back up
to 120,000/mm3. The psychiatrist reintroduced quetiapine
and scheduled a control platelet test 5 days later, which
showed a decrease to 84,000/mm3. In view of this positive
rechallenge, quetiapine was discontinued definitively. Fifteen
days after quetiapine discontinuation, the platelet count was
123,000/mm3.
In both situations, no other clinical or iatrogenic
parameter seemed to account for the onset of thrombocy-
topenia. To our knowledge, the second patient described
herein is the first case of quetiapine-induced thrombocy-
topenia with positive rechallenge to be in the literature.
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A 26-year-old Brazilian woman with a history of club drug
use, in addition to cannabis and alcohol use, was referred
to a clinic for substance abuse treatment after being found
unconscious by security guards at a street party. Upon
admission, the patient reported that she started using
psychoactive substances when she was 16 years old.
At that occasion, she ran away from home and started
living with a friend who was a synthetic drug dealer.
Motivated by the availability of drugs at a low price, and
being in close contact with drug users, she started to
increasingly use drugs such as 3,4-methylenedioxy-
methamphetamine (MDMA). Increased consumption led
to increased tolerance, and as a result she started to look
for substances with more powerful and longer-lasting
effects. Eight months before admission, she started using
NBOMe (25I-NBOMe) weekly at electronic music parties,
having as many as four blotters per week. While
intoxicated, the patient reported engaging in moral and
sexual exposure, including being nude and masturbating in
public and having unprotected sex with several different
partners. After these events, she would not remember
anything about the actions, locations or individuals with
whom she had been. As she started treatment, she was
tested for HIV and had a positive result. A diagnosis of other
hallucinogen use disorder – NBOMe (304.50 – F16.20
severe) and conduct disorder (312.82 – F16.20 moderate)
was established according to DSM-5 and ICD-11.
There is a growing international concern over the
manufacturing and distribution of synthetic analogs of
controlled substances as an attempt to circumvent drug
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laws and evade interdiction. In fact, the consumption of
these substances has become a public health problem in
many parts of the world. Controlled substance analogs
include a large number of substituted phenethylamines; of
these, the NBOMe series, a generic denomination for
phenethylamines, has been attracting attention from med-
ical and legal authorities due to the high number of cases of
intoxication, followed or not by death – including in Brazil.1
This growing class of potent stimulant and hallucino-
genic synthetic substances has effects similar to those of
LSD and can severely affect the central nervous system.2
Recreational users of NBOMe refer hallucinogenic and
dissociative effects and feelings of euphoria, fear, and
paranoia. Effects range from mild to severe changes in
cognition, mood and affect, with powerful sensory/somatic
effects and mystical experiences.3
According to the United Nations Office on Drugs and
Crime,4 substances such as the 2C series (e.g., 2C-I) and
NBOMe compounds are present in 17% of the world
market of new psychoactive substances. NBOMe drugs
have been sold as an alternative to LSD, with the price
of a blotter ranging from R$ 30 to R$ 40.4
Data on the prevalence of NBOMe use is available from
only two subpopulation surveys of individuals attending
nightclubs in the United States and England. In the first
study, 582 of 22,289 (2.6%) respondents of the 2013
Global Drug Survey reported having used an NBOMe, the
most common type being 25I-NBOMe (442 of the
respondents, 2.0% of the whole cohort, and 75.9% of
those who had used an NBOMe).2 The second study
surveyed 397 clubbers in London in 2013: 11.8% of the
interviewees had heard of NBOMe drugs (compared with
96.0% for mephedrone), and 4.8% had used an NBOMe
(compared with 76.6% for mephedrone).2
To the best of our knowledge, only one Brazilian study
has so far been published on NBOMes.5 In that study,
77 blotters seized on the streets were analyzed; 66.7% of
the samples contained one or more types of NBOMes,
confirming the growing presence of these novel substances
in the market. According to the author, users are often
misled to believe that they are taking LSD, when in
fact they are taking new, little known drugs like NBOMes
or other substituted phenethylamines.5 The scarcity
of research on the topic and the fact that intoxication
reactions associated with these drugs are still unknown
provide further grounds for concern in clinical practice.
Lysa Remy,1 Nino Marchi,1 Juliana Scherer,1
Tais R. Fiorentin,1,2 Renata Limberger,1,2
1 Felix Kessler1
1Center for Drug and Alcohol Research, Hospital de Clı´nicas de
Porto Alegre, Universidade Federal do Rio Grande do Sul (UFRGS),
Porto Alegre, RS, Brazil. 2Graduate Program in Pharmaceutical
Sciences, School of Pharmacy, UFRGS, Porto Alegre, RS, Brazil
Submitted Jul 10 2015, accepted Aug 04 2015.
Acknowledgements
This study was supported by Fundo de Incentivo a
Pesquisa e Eventos – Hospital de Clı´nicas de Porto
Alegre (FIPE-HCPA; grant GPPG-HCPA 07-391).
Disclosure
The authors report no conflicts of interest.
References
1 Pagnan R, Turollo Jr R. Estudante encontrado morto usou droga e se
afogou na USP, diz laudo [Internet]. Folha de Sa˜o Paulo. 2014 Oct 16
[cited Jun 30 2015]. http://www1.folha.uol.com.br/cotidiano/2014/10/
1533238-estudante-encontrado-morto-usou-droga-e-se-afogou-na-usp-
diz-laudo.shtml.
2 Wood DM, Sedefov R, Cunningham A, Dargan PI. Prevalence of use
and acute toxicity associated with the use of NBOMe drugs. Clin
Toxicol (Phila). 2015;53:85-92.
3 Erowid.org [Internet]. 25I-NBOMe, legal status. [cited 2015 Jun 15].
https://www.erowid.org/chemicals/2ci_nbome/2ci_nbome_law.shtml.
4 United Nations Office on Drugs and Crime (UNODC). World drug
report 2014. Vienna: UNODC; 2014.
5 Coelho Neto J. Rapid detection of NBOME’s and other NPS on blotter
papers by direct ATR-FTIR spectrometry. Forensic Sci Int. 2015;
252:87-92.
Rev Bras Psiquiatr. 2015;37(4)
352 Letters to the Editors
Flavio Pechansky,
CORRIGENDUM
We hereby inform that there was an error in the sixth author’s surname in the letter entitled ‘‘NBOMe: a new
dangerous drug similar to LSD,’’ by Lysa Remy et al., published in this journal in volume 37, issue 4, pages 351-352:
‘‘Flavio Pechanky’’ should read ‘‘Flavio Pechansky.’’ This is how the letter should be cited: Remy L, Marchi N,
Scherer J, Fiorentin TR, Limberger R, Pechansky F, Kessler F. Rev Bras Psiquiatr. 2015;37:351-2.
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